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Abstract
Objective: To evaluate the utility of entheseal ultrasonography and serum COMP in the preclinical diagnosis of psoriatic arthritis.
Methods: 60 psoriatic patients were divided into: 30 patients with psoriasis (group I) and 30 patients with psoriatic arthritis as control 
(group II). They underwent independent clinical and ultrasonographic examination of both lower limbs at the calcaneal insertions of 
Achilles tendons. Psoriatic arthritis disease activity and severity was assessed by modified DAS28 and Steinbrockers scores. Serum 
levels of COMP were measured for all patients by ELISA.
Results: On clinical examination, no entheseal abnormalities were detected in group I while they were present in 23.3% of group II with 
statistically significant difference between them (P  0.001). Ultrasonographic entheseal abnormalities were detected in 33.3% of group I 
and in 46.7% of group II with no significant difference between them (P  0.05). Serum COMP were significantly elevated in group I and 
II with no statistically significant difference between them (mean ± SD 5.9 ± 3 and 6.8 ± 12 respectively, P  0.05). Entheseal ultrasound 
was more specific (67%) while serum COMP was more sensitive (87%) in the preclinical diagnosis of psoriatic arthritis. Serum COMP 
levels were significantly correlated with CRP in both groups and with DAS28 and Steinbrockers scores in group II (P  0.01).
Conclusion: Entheseal ultrasonography and serum COMP levels may be used complementary to each other for preclinical diagnosis of 
psoriatic arthritis. Serum COMP seems to be promising prognostic marker for psoriatic arthritis patients.
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Introduction
Psoriasis  is  a  chronic  genetically  determined  and 
immunomediated  inflammatory  skin  disease  that 
affect approximately 2% of the population. In its typi-
cal form, psoriasis results in patches of thick, red skin 
covered with silvery scales.1
Psoriatic  arthritis  is  an  inflammatory  rheumatic 
joint disease associated with psoriasis and commonly 
included  among  seronegative  forms  of  spondyloar-
thropathy.2 It affects 2%–3% of the population, however 
its incidence has been rising over the last 30 years.3
In approximately 6%–39% of patients, psoriasis is 
present many years before the onset of arthritis.4
Psoriatic  arthritis  damages  cartilage,  synovium 
and bone of the joints causing pain, impairment and 
disability making early recognition and intervention 
important.5  Its  marked  entheseal  involvement  (the 
origin and insertion of ligaments, tendons and joint 
capsules) is a distinctive clinical aspect that helps to 
discriminate it from other conditions observed at their 
onset such as rheumatoid arthritis. It may be isolated 
to tendon insertions such as the Achilles tendon or 
plantar fascia or be more diffuse including multiple 
ligamentous attachments.6
Current methods for diagnosis of and monitoring 
the disease are only able to detect clinical manifes-
tations of arthritis late in the process. However with 
the recent onset of successful treatments for inflam-
matory arthritis, it becomes important to identify fac-
tors that can predict the evolution of arthritis. This is 
especially critical in the early phases of the disease so 
that these treatments can started as soon as possible to 
slow down progression of the disease.7 Ultrasound has 
been increasingly used in rheumatology for assessing 
soft tissue involvement in patients with arthritis.8
Inspite of the high number of studies supporting 
its role and validity in the assessment of patients with 
rheumatoid arthritis and osteoarthritis, the potential 
role of ultrasound imaging in patients with psoria-
sis and psoriatic arthritis still waits to be adequately 
investigated including accuracy and reproducibility.9 
Ultrasound  particularly  when  coupled  with  power 
Doppler imaging can detect subclinical abnormali-
ties of soft tissues, tendons and ligaments especially 
enthesitis, which has been postulated to be the hall 
mark  and  the  initial  site  of  joint  inflammation  in 
spondyloarthropathies.10
Another  valuable  approach  to  monitor  arthritis 
would be by measuring biological markers of carti-
lage degradation and repair which reflect variations in 
joint remodeling. One such potential marker of arthri-
tis is cartilage oligomeric matrix protein (COMP).7
COMP is a tissue specific pentameric glycopro-
tein and one component of the extracellular articular 
cartilage matrix and belongs to the thrombospondin 
family.11 It was first detected in the serum and syno-
vial fluid of patients suffering from rheumatic disor-
ders such as rheumatoid arthritis and osteoarthritis.12 
However much less known about COMP production 
in synovial cells in other rheumatic diseases.13 Origi-
nally it is considered a marker of cartilage breakdown, 
but it has also been identified in tendons, ligaments 
and synovium.14 It has potential as a diagnostic and 
prognostic indicator and as a marker of the rheumatic 
disease severity and the effect of treatment.12,15
The aim of the present study was to evaluate the 
role of entheseal ultrasonography and serum COMP 
in the preclinical diagnosis of psoriatic arthritis.
subjects and Methods
The present case control study included 60 psoriatic 
patients based on clinical diagnosis. They were recruited 
from  Rheumatology,  Dermatology  Departments  and 
Rheumatology outpatient clinic, Ain Shams University 
hospital. Their ages ranged from 23–48 years. They 
were divided into 2 groups; group I included 30 patients 
with psoriasis without any typical joint symptoms or 
signs, and group II included 30 patients with psoriatic 
arthritis (who were diagnosed according to the classifi-
cation criteria for psoriatic arthritis CASPAR criteria)16 
as control group. Both groups were age and sex matched 
and also matched as regard duration of skin disease and 
severity of skin affection as assessed by the psoriasis 
area and severity index (PASI) score.17 Patients with 
evidence of other rheumatic diseases, malignancies and 
infections were excluded from the study. An informed 
consent was obtained from each patient. The study was 
approved by Ain Shams Medical Ethics Committee.
All patients were subjected to full history taking and 
thorough clinical examination including dermatologi-
cal and rheumatological examination to detect arthri-
tis, clinical dactylitis (swelling of an entire digit) and 
enthesitis (swelling, pain, tenderness along the course 
of the Achilles tendon or at the level of the calcaneal entheseal ultrasonography and serum COMP in preclinical diagnosis of psoriatic arthritis
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insertion or its functional impairment). For psoriatic 
arthritis patient only the disease activity was assessed 
by Modified Disease Activity Score (DAS28).18
Radiological  examination  was  done  for  all 
patients including:
a.  Plain X-ray on hands, feets, spine and sacroiliac 
joints, then the psoriatic arthritis disease severity 
was assessed by Modified Steinbrockers scoring 
method.19
b. Real time musculoskeletal ultrasonography using 
ESAOTE  MYLAB  70X  VISION.  (ESAOTE 
MEDICAL SYSTEM ITALY) with 9–11 MHz 
probe. An adequate amount of gel was used to 
obtain the best visualization of superficial soft 
tissues.  Subjects  were  not  allowed  to  assume 
nonsteroidal anti-inflammatory drugs three weeks 
before  ultrasound  examination.  The  examiner 
doctor was unaware of the clinical symptoms and 
signs of the patients. Longitudinal and transverse 
scans of Achilles tendons were obtained. Power 
Doppler  sonography  was  used  to  detect  the 
degree  of  vascularization  as  an  indirect  sign  of 
inflammation. Early ultrasound signs of enthesitis 
are loss of normal fibrillar echogenicity, hypoechoic 
swelling of the tendon insertion, effusion, increase 
of blood flow detectable with power Doppler.20,21
Laboratory studies
Five milliliters of venous blood were collected from 
each patient, 2 ml on EDTA for ESR by Westergren 
method and 3 ml in a plane tube where serum was 
collected and stored at -70o for subsequent assay of 
COMP and C-reactive protein (CRP). Three millili-
ters of blood were withdrawn from 20 age and sex 
matched  healthy  lab  workers  for  determination  of 
normal COMP values.
COMP was assayed by enzyme immunoassay using 
Human Cartilage Oligomeric Matrix Protein ELISA 
Kit (Biovendon Research and Diagnostic Products. Im 
Neuenheimer Feld 583. D-69120 Heidelburg Germany). 
The mean     ±   SD of serum COMP among healthy lab 
workers was 0.9 ± 0.28 mg/mL.
CRP was assayed by latex using Omega Diagnos-
tics Avitex (Omega diagnostics LTD. Omega house, 
Hillfoots business village, Alva FK12 5DQ, Scotland, 
United Kingdom).
Statistical  analysis  of  data  was  done  by  IBM 
computer using SPSS (statistical program for social 
science  version  12).  Mean  and  standard  deviation 
(SD) were used to describe quantitative variables 
and number and percentage for qualitative variables. 
Unpaired  t-test  was  used  to  compare  quantitative 
variables between both groups while Mann Whitney 
Willcoxon U test was used instead of t-test in non para-
metric data (SD  50% mean). Chi-square test was used 
to compare qualitative variables between both groups. 
Spearman correlation test was used to rank different 
variables against each others positively or inversely. 
P-values less than 0.05 were accepted to be statisti-
cally  significant. The  sensitivity,  specificity,  positive 
predictive value, negative predictive value and accu-
racy of both entheseal ultrasound and serum COMP of 
both groups were calculated from the following equa-
tions: Sensitivity = % True positive cases/True positive 
cases + false negative cases, Specificity = % True nega-
tive cases/True negative cases + false positive cases, 
Positive predictive value = % True positive cases/True 
positive cases + false positive cases, Negative predictive 
value = % True negative cases/True positive cases + false 
negative cases and Accuracy = % True positive cases + 
true negative cases/Total number of cases.22
Results
The present study was carried out on 60 psoriatic 
patients divided into 2 groups: group I included 
30 patients with psoriasis and group II included another 
30 patients with psoriatic arthritis as control group. No 
statistically significant difference was detected between 
both groups as regard age, sex, duration and severity of 
skin disease (P  0.05). While there was significant 
difference between them as regard clinical enthesitis 
and dactylitis and CRP (P  0.05) (Table 1).
Ultrasonographic findings
Achilles  tendinitis  was  the  predominant  feature  of 
enthesitis noted in the present study. Early ultrasound 
signs  of  enthesitis  included  loss  of  normal  fibril-
lar echogenicity, hypoechoic swelling of the tendon 
insertion, effusion, increase of blood flow detectable 
with power Doppler, retrocalcaneal bursitis and plan-
tar fasciitis. Achilles tendon and plantar fascia calci-
fications were also found in psoriatic arthritis patients 
(Fig.  1).  No  statistically  significant  difference  was Farouk et al
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Table 1. Comparison between group I and II patients as regard the main clinical features, ultrasonography and laboratory 
findings.
  Group I n = 30 Group II n = 30 P value
Age (years) mean (sD) 39 (5) 40 (5.9) 0.4 (ns)*
gender (n & %)  
  Male  
  Female
 
17 (56.7%)  
13 (43.3%)
 
12 (40%)  
18 (60%)
 
0.3 (ns)#
skin disease duration (years) mean (sD) 7.7 (1.2) 8.8 (3.0) 0.31 (ns)*
Duration of arthritis (years) mean (sD) – 1.7 (0.7) –
PAsI score mean (sD) 23 (4) 19.5 (5.8) 0.29 (ns)*
Clinical enthesitis and dactylitis (n & %) Zero 7 (23.3%) 0.0005 (hs)#
DAs 28 score mean (sD) – 4.6 (1.8) –
steinbrockers score mean (sD) – 23.4 (10) –
Ultrasonography of patients with entheseal 
abnormalities (n & %)
10 (33.3%) 14 (46.7%) 0.19 (ns)#
serum COMP (mg/ml) of patients with  
elevated levels  
n & %  
Mean (sD)
 
 
22 (73.3%)  
5.9 (3)
 
 
26 (86.7%)  
6.8 (12)
 
 
0.20 (ns)#  
0.37 (ns)≠
CrP (mg/ml) mean (sD) 11.9 (4) 24.5 (13) 0.03 (s)≠
*Unpaired t-test; #Chi-square test; ≠Mann Whitney test; 
Abbreviations: PAsI, psoriasis area and severity index; DAs 28, Disease activity score 28; COMP, cartilage oligomeric matrix protein; CrP, C-reactive 
protein.
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Figure 1. (A and c) Achilles tendon shows normal ultrasound appearance with thickness of about 3.5 mm at its insertion (normal less than 5.3 mm), no 
related fluid or abnormal vascularity seen. B) Achilles enthesopathy and retrocalcaneal bursitis, the Achilles insertional tract appears thickened (between 
arrowheads) and heterogeneously hypoechoic. A calcification (arrow) is evident within the distal portion of the tendon. The retrocalcaneal bursa is enlarged 
by fluid collection (asterisk). D) Plantar fasciitis, insertional tract is thickened (between arrowheads) and heterogeneously hypoechoic with thin linear 
calcification (arrow).
detected  between  psoriatic  and  psoriatic  arthritis 
patients  as  regard  these  ultrasonographic  findings 
(P  0.05) (Table 1) and (Fig. 2).
Serum COMP was significantly elevated in group I 
and II patients with no statistically significant difference 
between them as regard its mean levels (Table 1 and 
Fig. 2). While there was statistically significant differ-
ence between both groups as regard CRP Table 1. 
Serum COMP was more sensitive while entheseal 
ultrasonography was more specific in the preclinical entheseal ultrasonography and serum COMP in preclinical diagnosis of psoriatic arthritis
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diagnosis  of  psoriatic  arthritis,  both  had  the  same 
accuracy (Table 2).
Serum COMP correlated significantly with CRP 
in both group I and II (r = 0.57, 0.86 respectively, 
P = 0.003) and with modified DAS28 and modified 
Steinbrockers scores in group II (r = 0.94 and 0.88 
respectively, P = 0.0002). While no correlation was 
found between serum COMP and PASI score in both 
groups (r = 0.069 and 0.18 respectively, P = 0.09).
Discussion
Psoriatic arthritis occurs in up to one-third of patients 
with psoriasis.23 Usually the skin disease precedes the 
onset of psoriatic arthritis with two thirds of patients 
developing psoriasis before the onset of arthritis.24
Enthesopathic  changes  have  been  suggested  as 
being the unifying feature of the clinical subtypes of 
psoriatic arthritis, and the disease can be considered 
an enthesis associated disorder rather than primary 
synovitic arthropathy.25
So we aimed in this work to evaluate the role of 
entheseal utrasonography and serum COMP in the 
preclinical diagnosis of psoriatic arthritis.
In the present study despite there was significant 
difference  between  psoriatic  and  psoriatic  arthritis 
patients as regard clinical enthesitis, however ultraso-
nography showed almost the same entheseal abnor-
malities with no significant difference between them.
The Achilles tendons are among the most frequent 
sites  of  enthesopathic  involvement  in  psoriatic 
Figure 2. Comparison between group I and II as regard percentages of patients who had elevated serum cartilage oligomeric matrix protein and ultrasound 
entheseal abnormalities.
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Table 2. Sensitivity, specificity, PPV, NPV and accuracy of entheseal ultrasound and serum COMP in the preclinical 
diagnosis of psoriatic arthritis.
  entheseal ultrasound serum cOMp
True positive cases (psoriatic arthritis patients with positive test) (n) 14 26
True negative cases (psoriatic patients with negative test) (n) 20 8
False positive cases (psoriatic patients with positive test) (n) 10 22
False negative cases (psoriatic arthritis patients with negative test) (n) 16 4
sensitivity (%) 47% 87%
Specificity (%) 67% 27%
PPV (%) 58.3% 54%
nPV (%) 55.6% 66.7%
Accuracy (%) 56.8% 56.8%
Abbreviations: PPV, Positive predictive value; nPV, negative predictive value.Farouk et al
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arthritis. Ultrasound has shown that enthesitis can be 
asymptomatic and that some cases of Achilles tendi-
nitis can go undiagnosed. It allows visualization of 
lesions less than 5 mm in diameter and identification 
of minimal amounts of fluid at the level of the tendon, 
peritendinous structures and serous bursae. The high 
specificity of ultrasound allow its use as a comple-
mentary procedure when clinical examination yields 
normal  findings  because  the  signs  of  involvement 
are mild and may be not accompanied by specific 
symptoms.26
Simone  et  al27  found  sonographic  evidence  of 
involvement of the Achilles tendon in 35 of 59 pso-
riatic patients whereas clinical examination yielded 
18 diagnosis of Achilles tendinitis. These results lent 
support to the hypothesis of frequent enthesopathic 
involvement in psoriatic arthritis.
Power Doppler ultrasonography provides informa-
tion on the perfusion of the synovial tissue, tendons 
and entheses, so very slight changes in vascularity 
can be easily detected.10,21
In the present study, the sensitivity of ultrasound 
in the preclinical diagnosis of psoriatic arthritis was 
47%,  while  its  specificity  was  67%.  Weiner  and 
Coworkers28 found that the sensitivity of ultrasound 
in the detection of overall joint pathology in painful 
and/or swollen joint in psoriatic arthritis was 71%, 
and in clinically unaffected joints was 17%, while its 
specificity ranged between 84% and 94% depending 
on the joint pathology.
The low cost and the acceptable specificity suggest 
that ultrasound is a useful imaging tool in early psori-
atic arthritis. Ozçakar et al29 found that the percentage 
of asymptomatic enthesopathy detected by ultrasound 
in psoriatic patients was 56%, they strongly believed 
that ultrasound has an advantageous role in rendering 
the enthesopathy in psoriasis patients whether or not 
they are symptomatic.
COMP expressed primarily in cartilage, ligament 
and tendon.14 It is considered a marker of early carti-
lage breakdown in patients with psoriatic arthritis.30 It 
was also found elevated in the serum of patients with 
rheumatoid arthritis31 and osteoarthritis.12 In the pres-
ent study serum COMP was significantly elevated in 
both psoriatic and psoriatic arthritis patients with no 
significant difference between them. The increased 
serum COMP levels in patients with psoriasis propose 
that patients with psoriatic skin lesions might have 
additional joint involvement.13
T cells and proinflammatory cytokines like tumor 
necrosis factor-α (TNF-α) play an essential role in 
the pathogenesis of psoriasis and psoriatic arthritis. 
They stimulate chondrocytes to release destructive 
proteases  which  lead  to  loss  of  proteoglycans,  to 
destruction of collagen bundles and to the release of 
COMP.13 Despite the presence of previous studies on 
the utility of ultrasound and serum COMP in many 
rheumatic diseases, their combined validity, sensitiv-
ity and specificity in patients with psoriasis and psori-
atic arthritis has not been previously reported.
In the present study the sensitivity of serum COMP 
in the preclinical diagnosis of psoriatic arthritis was 
87% while its specificity was only 27%. The lack of 
specificity of serum COMP for cartilage may limit its 
use in assessing changes in joint damage in arthritis. 
The assay may need to be complemented by radio-
graphic or MRI evaluation.7
In patients with symptoms and clinical signs of hip 
pathology but not radiographic evidence of osteoarthri-
tis, a significant association was found between serum 
COMP and hip-related symptoms. This would support 
the use of serum COMP as a biomarker of hip joint 
pathology prior to radiographic findings.32 In the present 
study serum COMP levels have been demonstrated as an 
indicator for disease activity and severity in patients with 
psoriatic arthritis as it was significantly correlated with 
modified  DAS28  and  modified  steinbrockers  scores. 
Also significant correlation was found between serum 
COMP levels and laboratory disease activity in psori-
atic patients. While no correlation was found between 
serum COMP and the extent of skin disease in both 
psoriatic and psoriatic arthritis patients. Skoumal et al13 
couldn’t find any evidence that extended skin lesions of 
psoriasis have any influence on serum COMP and thus 
its elevated levels were due to on going joint inflamma-
tion. Patients with active psoriatic arthritis showed sig-
nificantly elevated serum COMP levels compared to the 
patients with low clinical and laboratory disease activ-
ity.13 This reflects increased cartilage tumour in inflam-
matory diseases with high activity similar to findings in 
rheumatoid arthritis.33 Serum COMP levels were signifi-
cantly high in rheumatoid arthritis patients positive for 
bone erosions on MRI compared with those who were 
negative for bone erosions, this may reflect joint damage entheseal ultrasonography and serum COMP in preclinical diagnosis of psoriatic arthritis
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that is dependent on the synovial inflammatory process 
in early rheumatoid arthritis.34
conclusion
Entheseal ultrasonography and measurement of serum 
COMP may be used for all patients with psoriasis for 
preclinical diagnosis of psoriatic arthritis to get the 
benefit of the high sensitivity of serum COMP and the 
high specificity of ultrasound. In addition serum COMP 
seems to be promising marker of disease activity and 
severity in psoriatic arthritis patients. These findings 
might have an influence on the clinical decision in 
patients with psoriasis and psoriatic arthritis, and have 
implication for therapy since the new biologic drugs 
can delay or stop joint damage when given in time. 
Further prospective studies for patients with psoriasis 
without history of arthritis are needed to clarify the 
value of entheseal ultrasound and serum COMP in 
detecting their progression to psoriatic arthritis.
Abbreviations
COMP, cartilage oligomeric matrix protein; DAS28, 
Disease  activity  score  28;  ELISA,  Enzyme  linked 
immunosorbent assay.
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